Current Report Filing (8-k)
February 01 2017 - 8:32AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported)
February
1, 2017 (February 1, 2017)
HEMISPHERX
BIOPHARMA, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
0
-
27072
|
|
52-0845822
|
(state
or other juris-
|
|
(Commission
|
|
(I.R.S.
Employer
|
diction
of incorporation)
|
|
File
Number)
|
|
(Identification
No.)
|
1617
JFK Boulevard, Suite 500, Philadelphia, PA
|
|
19103
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
|
|
|
|
Registrant's
telephone number, including area code:
(215) 988-0080
|
|
|
|
1617
JFK Boulevard, Suite 500, Philadelphia, PA 19103
|
|
(Former
name or former address, if changed since last report)
|
|
|
|
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
|
|
|
|
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
|
|
|
|
|
|
Item
7.01. Regulation FD Disclosure.
On
February 1, 2017, we issued a stockholder letter attached hereto as Exhibit 99.1. In accordance with General Instruction
B.2 of Form 8-K, the information set forth herein is deemed to be “furnished” and shall not be deemed to be “filed”
for purposes of the Securities Exchange Act of 1934, as amended.
Exhibit No.
|
Description
|
|
|
99.1
|
Stockholder
Letter of Hemispherx Biopharma, Inc. dated February 1, 2017*
|
*
The following exhibit relating to Item 7.01 is intended to be furnished to, not filed with, the SEC pursuant to Regulation FD.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
HEMISPHERX
BIOPHARMA, INC.
|
February
1, 2017
|
|
|
By:
|
/s/ Thomas
K. Equels
|
|
|
Thomas
K. Equels, President
|
Hemispherx Biopharma (AMEX:HEB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Hemispherx Biopharma (AMEX:HEB)
Historical Stock Chart
From Sep 2023 to Sep 2024